This study is in progress, not accepting new patients

Long Term Extension Study in Patients With Primary Hyperoxaluria

a study on Hyperoxaluria Kidney Disease

Summary

Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Official Title

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

Keywords

Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3), Primary Hyperoxaluria, PH1, PH2, RNAi, GalNAc, LDHA, LDH, siRNA, PH3, Inborn Genetic Diseases, DCR-PHXC, Open Label

Eligibility

Locations

  • Clinical Research Site
    San Francisco California 94143 United States
  • Clinical Trial Site
    Rochester Minnesota 55905 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
ID
NCT04042402
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 75 study participants
Last Updated